Adverse dermatoneurological events and impacts on daily activities of patients with gastrointestinal neoplasms undergoing chemotherapy

Rafaela Moreira da Silva Canille Corresponding author: Rafaela Moreira da Silva Canille, E-mail: rafaelacanille@yahoo.com.br

contributed to the conception or design of the study/research

contributed to the analysis and/or interpretation of the data

contributed to the final revision with critical and intellectual participation in the manuscript

Hospital de Base de São José do Rio Preto. São José do Rio Preto, São Paulo, Brazil

Maria Helena Pinto

contributed to the conception or design of the study/research

contributed to the analysis and/or interpretation of the data

contributed to the final revision with critical and intellectual participation in the manuscript

Faculdade de Medicina de São José do Rio Preto. São José do Rio Preto, São Paulo, Brazil

Katia Jaira Galisteu

contributed to the conception or design of the study/research

Faculdade de Medicina de São José do Rio Preto. São José do Rio Preto, São Paulo, Brazil

Rildo César Czorny

contributed to the analysis and/or interpretation of the data

União Faculdade dos Grandes Lagos. São José do Rio Preto, São Paulo, Brazil

Luana Gaino Bertolazzi

contributed to the analysis and/or interpretation of the data

Serviço Nacional de Aprendizagem Comercial. Barretos, São Paulo, Brazil

Tamara Veiga Faria

contributed to the analysis and/or interpretation of the data

contributed to the final revision with critical and intellectual participation in the manuscript

Faculdade Ceres. São José do Rio Preto, São Paulo, Brazil

Corresponding author: Rafaela Moreira da Silva Canille, E-mail: rafaelacanille@yahoo.com.br

	n (%)
Location
Colon	24 (66.7)
Stomach	7 (19.4)
Rectum	3 (8.3)
Esophagus	2 (5.6)
Treatment purpose
Adjuvant	17 (47.2)
Palliative	17 (47.2)
Neoadjuvant	2 (5.6)
Antineoplastic protocol
Capecitabine + Oxaliplatin	30 (83.2)
Capecitabine + Bevacizumab	2 (5.6)
Capecitabine	2 (5.6)
Capecitabine + Gemcitabine	1 (2.8)
Capecitabine + Epirubicin + Oxaliplatin	1 (2.8)

Cycle	Absent HFS			Present HFS			p value
	ADL score			ADL score
	n	Median Min; Max	SD	n	Median Min; Max	SD
Two	22	13.0	14.2	9	21.0	27.9	0.176
Two	22	0.0 ; 62.0	14.2	9	11.0 ; 95.0	27.9	0.176
Three	8	21.0	12.29	21	24.0	11.64	0.864
Three	8	0.0 ; 38.0	12.29	21	10.0 ; 58.0	11.64	0.864
Four	3	19.0	7.02	27	22.0	15.41	0.406
Four	3		7.02	27	0.0 ; 78.0	15.41	0.406

CIPN		Activities of daily living in cycles
CIPN		Cycle 1 ADL	Cycle 2 ADL	Cycle 3 ADL	Cycle 4 ADL	Cycle 5 ADL	Cycle 6 ADL	Cycle 7 ADL	Cycle 8 ADL
Cycle 1	Coefficient r	0.801^**	0.633^*	0.571^*	0.602^*	0.636^*	0.541^*	0.674^*	0.846^**
	p value	< 0.001	< 0.001	0.001	< 0.001	0.001	0.011	0.023	0.071
	n	35	30	29	30	24	21	11	5
Cycle 2	Coefficient r	0.576^*	0.69^*	0.618^*	0.743^*	0.662^*	0.749^*	0.93^**	0.985^**
	p value	0.001	< 0.001	0.001	< 0.001	0.001	0.001	0.001	0.112
	n	31	31	26	25	20	16	8	3
Cycle 3	Coefficient r	0.538^*	0.53^*	0.692^*	0.719^*	0.667^*	0.761^**	0.746^*	0.971^**
	p value	0.002	0.005	< 0.001	< 0.001	0.001	< 0.001	0.034	0.029
	n	30	26	29	26	21	19	8	4
Cycle 4	Coefficient r	0.412	0.534^*	0.785^**	0.721^*	0.640^*	0.588^*	0.675^*	0.911^**
	p value	0.024	0.006	< 0.001	< 0.001	0.001	0.006	0.023	0.031
	n	30	25	25	30	23	20	11	5
Cycle 5	Coefficient r	0.629^*	0.697^*	0.737^*	0.686^*	0.744^*	0.705^*	0.770^**	0.879^**
	p value	0.001	0.001	< 0.001	< 0.001	< 0.001	0.002	0.015	0.121
	n	23	18	19	22	22	17	9	4
Cycle 6	Coefficient r	0.585^*	0.721^*	0.714^*	0.670^*	0.583^*	0.609^*	0.731^*	0.804^**
	p value	0.004	0.001	0.001	0.001	0.009	0.003	0.016	0.101
	n	22	17	19	20	19	21	10	5
Cycle 7	Coefficient r	0.677^*	0.651^*	0.770^**	0.663^*	0.632^*	0.760^**	0.763^**	0.914^**
	p value	0.011	0.042	0.015	0.014	0.037	0.004	0.006	0.030
	n	13	10	9	13	11	12	11	5
Cycle 8	Coefficient r	0.738^*	0.890^**	0.968^**	0.752^**	0.879^**	0.825^**	0.745	0.909^**
	p value	0.155	0.301	0.032	0.143	0.121	0.085	0.255	0.032
	n	5	3	4	5	4	5	4	5

Brasil